Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.

@article{Hoff1991PhaseIS,
  title={Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.},
  author={D. D. Von Hoff and Sylvan Green and David S. Alberts and Donna Stock-Novack and Earl A. Surwit and Thomas P. Miller and Ronald L. Stephens},
  journal={American journal of clinical oncology},
  year={1991},
  volume={14 3},
  pages={193-4}
}
Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.